Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 11/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381597 | 0.84 | PIK3CD (0.48) | AKT1PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3381643 | 0.83 | AKT1 (0.65) | AKT1HSD17B10PIK3CAPIK3CDPIK3CB | |
| SCHEMBL28734098 | 0.82 | MAP4K4 (0.49) | AKT1HSD17B10KDM4EMAPTALDH1A1 | |
| SCHEMBL3378290 | 0.80 | AKT1 (0.62) | AKT1HSD17B10PIK3CAPIK3CDPIK3CB | |
| SCHEMBL10296750 | 0.79 | AKT1 (1.00) | AKT1PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL12476085 | 0.78 | AKT1 (0.78) | AKT1PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3378287 | 0.77 | AKT1 (0.61) | AKT1HSD17B10SIRT2SIRT1KDM4E | |
| SCHEMBL12909207 | 0.74 | KMT2A (0.44) | HSD17B10PIK3CAPIK3CDPIK3CBKDM4E | |
| SCHEMBL18342017 | 0.74 | HSD17B10 (0.54) | AKT1HSD17B10PIK3CAPIK3CDPIK3CB | |
| SCHEMBL18341910 | 0.74 | AKT1 (0.59) | AKT1HSD17B10PIK3CAPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-1497287-B1 | Quinoline derivatives in combination with 5-FU or CPT-11 for use in the treatment of cancer | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| US-7598268-B2 | Quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1539754-A4 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20040006101-A1 | Quinolinone derivatives | CHIRON CORPORATION | 2004-01-08 | — | — | US | disclosed |
| WO-2003087095-A1 | QUINOLINONE DERIVATIVES | CHIRON CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030158224-A1 | Quinolinone derivatives | CHIRON CORPORATION | 2003-08-21 | — | — | US | disclosed |
| US-6605617-B2 | Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase | CHIRON CORPORATION | 2003-08-12 | — | — | US | disclosed |
| EP-1317442-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20030028018-A1 | Quinolinone derivatives | CHIRON COPORATION | 2003-02-06 | — | — | US | disclosed |
| US-20020107392-A1 | Quinolinone derivatives | NOVARTIS AG (CH) | 2002-08-08 | — | — | US | disclosed |
| WO-2002022598-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | AKT1 4488/4885HSD17B10 498/4885PIK3CA 1004/4885 |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | AKT1 4339/4885HSD17B10 754/4885PIK3CA 2441/4885 |
| US-20030028018-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | AKT1 4378/4885HSD17B10 540/4885PIK3CA 926/4885 |
| US-20030158224-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | AKT1 4378/4885HSD17B10 540/4885PIK3CA 926/4885 |
| US-20020107392-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | AKT1 4378/4885HSD17B10 540/4885PIK3CA 926/4885 |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | AKT1 4488/4885HSD17B10 498/4885PIK3CA 1004/4885 |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | AKT1 4348/4885HSD17B10 755/4885PIK3CA 2374/4885 |
| US-20040006101-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | AKT1 4378/4885HSD17B10 540/4885PIK3CA 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.